Notably, all approved EGFR TKIs are gene-type specific and much less efficient in patients with wtEGFR amplification or other insensitive mutant EGFRs (such as Ex20ins); thus, there is still a large part of NSCLC patients who cannot benefit from current EGFR-targeting therapeutic strategies. This evidence concerns the gene EGFR and non-small cell lung carcinoma.